The above evidence indicates that XPG expression was positively associated with a number of clinicopathological parameters reflecting GC development, and might thus play important roles in the initiation and progression of GC and serve as a biomarker for GC development, predicting biological activities and degree of progression. Here, ERCC5 is linked to gastric cancer.